SEPTEMBER:
- Renalytix initiates KidneyIntelX Testing at Mount Sinai, with its first live EHR Integration.
AUGUST:
- Renalytix announces partnership with Astra-Zeneca, teaming up to improve CKD treatments and outcomes.
- Renalytix files submission with FDA, seeking clearance of its KidneyIntelX test platform.
- Renalytix commences with a KidneyIntelX Multi-Center Study to monitor & predict kidney risk in COVID-19 patients.
JULY:
- Renalytix raises $85.1M on the NASDAQ Global Market in the U.S.
- Renalytix signs agreement to become a provider in the America’s Choice Provider Network, one of the largest, preferred networks in the US with members and providers in all 50 states and agreement with 1700+ payers.
